Customer Center
Login | Register

xTAG® Respiratory Viral Panel FAST v2

Respiratory Virus Detection with xTAG® Respiratory Viral Panel

Gain confidence in your diagnosis with the comprehensive, multiplex xTAG RVP assay

Respiratory Viruses and Diagnostic Testing

 

Early and accurate detection of respiratory viruses is critical to improving patient outcomes and preventing the spread of disease. It is known that:

 

  • There are many respiratory pathogens—viral and bacterial—commonly encountered in a clinical setting
  • Many of these pathogens present with similar symptoms
  • Patients with flu-like symptoms are sometimes sent home without treatment or are treated with incorrect medications

 

The Centers for Disease Control (CDC) states that viral infections are a major cause of hospitalizations in young children and the elderly, and represent the seventh leading cause of death in the United States,1 with annual direct and indirect costs estimated at more than US $10 billion per year.2 From influenza alone, each year, over 200,000 Americans are hospitalized and 36,000 of them die from their infection.1 A New England Journal of Medicine study of children with influenza showed that only 28% of hospitalized and 17% of outpatient children were accurately diagnosed by their physician, echoing the need for rapid influenza testing.3

 

Detect multiple respiratory viruses, the majority of which readily circulate among the most vulnerable populations—children, the elderly, and the immunocompromised—with xTAG® Respiratory Viral Panel (RVP).

Comprehensive

Tests for 19 different respiratory viruses including Flu A subtypes (H1, H3 and H1N1 (2009)) in a single assay

Reliable

Excellent clinical sensitivity and specificity
 

Efficient

Results available in a single working day to impact patient treatment

The Luminex Solution

 

The xTAG RVP FAST v2 assay is a qualitative nucleic acid multiplex test intended for the simultaneous detection and identification of multiple respiratory virus nucleic acids from nasopharyngeal swabs from individuals suspected of respiratory tract infections. This robust assay uses the proprietary Luminex xTAG Technology and xMAP® Technology platform to detect multiple targets in a single sample, enabling more accurate and efficient patient diagnosis.

 

The xTAG RVP FAST v2 assay includes two controls (MS-2 and Lambda DNA) to ensure assay performance.

 

The following table shows clinical targets detected by each respiratory viral panel based on regional regulatory clearances.

 

Viral Subtypes CE Marked in EU and
SFDA Approved
Respiratory Syncytial Virus (RSV)
  RSV A  
  RSV B  
Influenza A
  Influenza A matrix
  H1 subtype
  H3 subtype
  H5 subtype  
Influenza B
Parainfluenza 1
Parainfluenza 2
Parainfluenza 3
Parainfluenza 4
Metapneumovirus (hMPV)
Adenovirus
Entero-Rhinovirus (Reported as Rhinovirus only in US.)
Corona NL63
Corona HKU1
Corona 229E
Corona OC43
Bocavirus
Controls
xTAG MS-2 Bacteriophage Internal Control
xTAG bacteriophage Lambda DNA Control

Ordering Information

 

Luminex Online Order Management
Email: [email protected]
Phone: +31 (0)73 800 1900
Fax: +31 (0)73 800 1998
Product Name Kit Size Registration Status Part Number
xTAG Respiratory Viral Panel FAST v2
(RVP FAST v2)
96 Tests CE Marked in EU
SFDA Approved
I040C0413

Resources

 

xTAG Respiratory Viral Panel (RVP)Clinician Brochure


Evaluation of a multiplex Respiratory Viral Panel—xTAG RVP FAST v2 on MAGPIX for rapid identification of respiratory viruses and performance on External Quality Assessment panelsPoster


Clinical Evaluation of the ID-Tag RVP Test for Detection of Respiratory VirusesPoster


Establishing the Epidemiology of Respiratory Virus Infections Using Molecular TechnologyPoster


Simultaneous Detection of 17 Respiratory Viruses and Subtypes with the Luminex Diagnostics Respiratory Virus Panel KitPoster


Evaluation of the Luminex Diagnostics Respiratory Viral Panel for the Detection of 16 Respiratory Viruses and Subtypes in ChildrenPoster


Multiplexed Molecular Testing for the Detection of Human Respiratory Viruses using the TM Bioscience ID-Tag RVP AssayPoster


Preliminary Evaluation of the New Version of Luminex Respiratory Viral Panel (xTAG RVP FAST v2)Poster


Performance Characteristics of the xTAG® Respiratory Viral Panel FAST: A Multi-Center Clinical EvaluationPoster


Better Know Your xTAG RVP Buffers!Luminex Blog


Why Test for Respiratory Viruses in Your Clinical Diagnostics Lab?Luminex Blog

 

 

Note: Luminex manufactures and distributes products mentioned in the reference materials provided in this section. The reference materials may mention use of product that has not been approved or cleared by regulatory agencies in your region or territory. Luminex is providing reference materials for customer information and does not recommend using the product inconsistent with the product’s intended use and labeling.

  1. Centers for Disease Control. About the Flu; Influenza: The Disease. November, 2004. http://www.cdc.gov/flu/about/disease.htm. Accessed June 2006.
  2. White House Government National Strategy for Pandemic Influenza.
  3. Poehling KA, Edwards KM, et al. The under recognized burden of influenza in young children. N Engl J Med 2006; 355(1):31-40.

 

For In Vitro Diagnostic Use. Products are region specific and may not be approved in some countries/regions. Please contact Luminex at [email protected] to obtain the appropriate product information for your country of residence.

*Only xTAG RVP FAST v2 can be used on our MAGPIX system.

Intended Use (EU-IVD/SFDA Approved):

The xTAG® Respiratory Viral Panel Fast v2 (RVP FAST v2) is a qualitative nucleic acid multiplex test intended for the simultaneous detection and identification of multiple respiratory virus nucleic acids in nasopharyngeal swabs, nasal aspirates and bronchioalveolar lavages from individuals suspected of respiratory tract infections.

The detection and identification of specific viral nucleic acids from individuals exhibiting signs and symptoms of respiratory infection aids in the diagnosis of respiratory viral infection when used in conjunction with other clinical and laboratory findings.